HemoShear LLC 's October announcement that a new application of its in vitro tissue modeling platform to tumors reproduces the human response to cisplatin means the company could soon tap into business from drug developers...

Although there is widespread agreement on the need for a better way to diagnose preeclampsia, few companies have pursued new tests because finding specific markers has been difficult. A Yale-led group has found dye-binding aggregates...

Baylor College of Medicine researchers have uncovered a pathway in allergic asthma that opens up the potential for developing therapeutics that target the causes of the disease rather than just its symptoms. 1 The team...

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Atherosclerosis Dickkopf homolog 1 (DKK1) Cell culture studies suggest inhibiting DKK1 could help treat atherosclerosis. Endothelial-to-mesenchymal transition contributes to calcification and fibrosis in atherosclerosis....

NIH researchers have shown that sphingosine 1-phosphate receptor agonists such as Novartis AG 's Gilenya fingolimod could transiently reduce P glycoprotein -mediated drug efflux and enhance drug delivery to the brain. 1 The group at...

An international team of researchers has used the endothelial protein DEL1 to treat periodontitis in mice. 1 Despite the therapeutic angle, the near-term utility of DEL1 is more likely to be as a diagnostic and...

A team at The Scripps Research Institute has designed a prodrug of doxorubicin that is activated by components of the tissue factor coagulation cascade present in high concentrations in the tumor microenvironment, thus avoiding off-target...

A group of Taiwanese researchers has shown that an antibody against IL-20 helped treat osteoporosis in mice. 1 The findings have grabbed the attention of Novo Nordisk A/S , which has an anti-IL-20 mAb in Phase...

A team of European researchers has identified a way to target proinflammatory dendritic cells that contribute to atherosclerotic plaques in mice. 1 Carolus Therapeutics Inc. has a nonexclusive option to license the findings and believes...

sanofi-aventis Group has seized an early stage opportunity that opened up when Biogen Idec Inc. recently refocused on neurology, by picking up an obesity and type 2 diabetes program centered on osteocalcin that was previously...